INDIVIOR PLC DL 050 (F:2IVB) — Market Cap & Net Worth
Market Cap & Net Worth: INDIVIOR PLC DL 050 (2IVB)
INDIVIOR PLC DL 050 (F:2IVB) has a market capitalization of $3.51 Billion (€3.01 Billion) as of June 17, 2026. Listed on the F stock exchange, this Germany-based company holds position #4551 globally and #775 in its home market, demonstrating a -0.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INDIVIOR PLC DL 050's stock price €27.00 by its total outstanding shares 125024430 (125.02 Million).
INDIVIOR PLC DL 050 Market Cap History: 2015 to 2026
INDIVIOR PLC DL 050's market capitalization history from 2015 to 2026. Data shows growth from $1.80 Billion to $3.95 Billion (6.54% CAGR).
INDIVIOR PLC DL 050 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INDIVIOR PLC DL 050's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 2IVB by Market Capitalization
Companies near INDIVIOR PLC DL 050 in the global market cap rankings as of June 17, 2026.
Key companies related to INDIVIOR PLC DL 050 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
INDIVIOR PLC DL 050 Historical Marketcap From 2015 to 2026
Between 2015 and today, INDIVIOR PLC DL 050's market cap moved from $1.80 Billion to $ 3.95 Billion, with a yearly change of 6.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.95 Billion | -10.00% |
| 2025 | €4.39 Billion | +156.41% |
| 2024 | €1.71 Billion | -14.47% |
| 2023 | €2.00 Billion | -33.53% |
| 2022 | €3.01 Billion | +34.42% |
| 2021 | €2.24 Billion | +173.15% |
| 2020 | €819.26 Million | +154.54% |
| 2019 | €321.86 Million | -63.56% |
| 2018 | €883.21 Million | -73.39% |
| 2017 | €3.32 Billion | +34.35% |
| 2016 | €2.47 Billion | +36.97% |
| 2015 | €1.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of INDIVIOR PLC DL 050 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.51 Billion USD |
| MoneyControl | $3.51 Billion USD |
| MarketWatch | $3.51 Billion USD |
| marketcap.company | $3.51 Billion USD |
| Reuters | $3.51 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About INDIVIOR PLC DL 050
Indivior Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extende… Read more